FIELD: biotechnology.
SUBSTANCE: invention relates to the biotechnology.
EFFECT: invention solves the problem of treating diseases, particularly systemic lupus erythematosus, with an antibody fragment specifically binding to CD154.
9 cl, 3 ex, 8 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| TACI-Fc FUSION PROTEIN AND ITS USE | 2019 |
|
RU2814988C2 |
| METHODS OF TREATING CONDITIONS WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR 1 RECEPTOR (CSF1R) | 2012 |
|
RU2670743C9 |
| METHOD AND COMPOSITION FOR REDUCTION OF MICROMOLECULE AGGREGATION UNDER PHYSIOLOGICAL CONDITIONS | 2009 |
|
RU2563823C2 |
| APPLICATION OF ANTI-CD40-ANTIBODIES | 2006 |
|
RU2442606C2 |
| ANTI-IFNAR1 ANTIBODIES WITH LOWER LIGAND Fc AFFINITY | 2009 |
|
RU2556125C2 |
| IMMUNOTHERAPEUTIC AGENT COMBINED WITH CD37, AND ITS COMBINATION WITH BIFUNCTIONAL CHEMOTHERAPEUTIC AGENT | 2009 |
|
RU2531754C2 |
| MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TO CD20 | 2018 |
|
RU2724469C2 |
| HUMAN VISTA ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2746994C2 |
| OPTIMIZED OPTIONS OF ANTI-VEGF ANTIBODIES | 2016 |
|
RU2763916C2 |
| SUBCUTANEOUS DOSING OF ANTI-CD38 ANTIBODIES | 2019 |
|
RU2810953C2 |
